At a Glance
- Market: AI in drug discovery
- 2025 value: USD 19.89 billion
- 2035 projection: USD 160.49 billion
- CAGR: 23.22%
- Drivers: Generative AI, multi-omics integration
What happened?
A new report projects the global AI in drug discovery market will grow from USD 19.89 billion in 2025 to USD 160.49 billion by 2035, expanding at a compound annual growth rate (CAGR) of 23.22%.
Why does it matter?
AI accelerates target identification, lead optimisation and trial design, reducing R&D timelines and costs by up to 30-50% in some workflows. Explosive growth reflects surging pharma investments in machine learning for handling vast omics datasets, predictive toxicology and virtual screening amid pressure to replenish pipelines faster.
Who’s behind it?
Market leaders include Exscientia, Insilico Medicine, BenevolentAI and Recursion, partnering with pharma giants like Sanofi, Pfizer and GSK. North America dominates with 45%+ share due to tech hubs and VC funding.
How was it achieved?
Advancements in generative AI (e.g., protein structure prediction), federated learning for data privacy and multi-modal models integrating genomics, proteomics and real-world evidence drive efficiency gains. Regulatory nods for AI tools (FDA’s 2025 guidance) further catalyse adoption.
What’s next?
By 2035, AI expected to contribute 20-30% of new drug approvals, with Asia-Pacific growing fastest at 25%+ CAGR. Challenges like data quality, bias mitigation and validation persist, but hybrid AI-human workflows will mature.
What are people saying?
Analysts: “Generative AI and multi-omics integration set to revolutionise discovery, slashing costs by 40%.”